Skip to Content
Merck
  • ENO1 Overexpression in Pancreatic Cancer Patients and Its Clinical and Diagnostic Significance.

ENO1 Overexpression in Pancreatic Cancer Patients and Its Clinical and Diagnostic Significance.

Gastroenterology research and practice (2018-02-28)
Hang Yin, Lei Wang, Hai-Lin Liu
ABSTRACT

We investigated in this study the expression of ENO1 in tissues and plasma of PDAC patients to evaluate its clinicopathological and diagnostic significance. ENO1 protein expression was detected in tissue microarray of human PDAC and adjacent noncancer tissues. Electrochemiluminescence immunoassay and amplified luminescent proximity homogeneous assay (AlphaLISA) were performed to measure CA19-9 and ENO1 concentration in plasma from PDAC patients and healthy controls. We demonstrated that ENO1 overexpression is positively correlated with clinical stage, lymph node metastasis, and poor prognosis of PDAC; ENO1 may function as a hopeful candidate diagnostic marker in combination with CA19-9 in PDAC diagnosis.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Monoclonal Anti-ENO1 antibody produced in mouse, clone 3C8, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Monoclonal Anti-ENO1 antibody produced in mouse, clone 8G8, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Anti-ENO1 (AB1) antibody produced in rabbit, IgG fraction of antiserum